Antimicrobial Sales and Use (ASU) Platform: Release notes
Submitted by Anonymous (not verified) on 18 September 2026 - 11:39
Antimicrobial Sales and Use (ASU) Platform: Release notes
Dynastat
Submitted by Anonymous (not verified) on 18 September 2026 - 11:35
Dynastat
NexoBrid
Submitted by Anonymous (not verified) on 18 September 2026 - 11:27
NexoBrid
Workshop on advancing proof-of-concept data in paediatric oncology drug development , Online, European Medicines Agency, Amsterdam, the Netherlands, from 21 September 2026, 13:00 (CEST) to 21 September 2026, 16:00 (CEST)
Submitted by Anonymous (not verified) on 18 September 2026 - 11:25
Workshop on advancing proof-of-concept data in paediatric oncology drug development , Online, European Medicines Agency, Amsterdam, the Netherlands, from 21 September 2026, 13:00 (CEST) to 21 September 2026, 16:00 (CEST)
Human medicines European public assessment report (EPAR): Adcomfo, omalizumab, Status: Opinion
Submitted by Anonymous (not verified) on 18 September 2026 - 11:05
Human medicines European public assessment report (EPAR): Adcomfo, omalizumab, Status: Opinion
Human medicines European public assessment report (EPAR): Frehemgo, denecimig, Status: Opinion
Submitted by Anonymous (not verified) on 18 September 2026 - 11:05
Human medicines European public assessment report (EPAR): Frehemgo, denecimig, Status: Opinion
Human medicines European public assessment report (EPAR): Inijaq, tofacitinib, Status: Opinion
Submitted by Anonymous (not verified) on 18 September 2026 - 11:05
Human medicines European public assessment report (EPAR): Inijaq, tofacitinib, Status: Opinion
Human medicines European public assessment report (EPAR): Lifyorli, relacorilant, Status: Opinion
Submitted by Anonymous (not verified) on 18 September 2026 - 11:05
Human medicines European public assessment report (EPAR): Lifyorli, relacorilant, Status: Opinion
Human medicines European public assessment report (EPAR): Pebrilzo, pertuzumab, Status: Opinion
Submitted by Anonymous (not verified) on 18 September 2026 - 11:05
Human medicines European public assessment report (EPAR): Pebrilzo, pertuzumab, Status: Opinion
Human medicines European public assessment report (EPAR): Povofortay, povorcitinib, Status: Opinion
Submitted by Anonymous (not verified) on 18 September 2026 - 11:05
Human medicines European public assessment report (EPAR): Povofortay, povorcitinib, Status: Opinion